Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Next Previous
Trial Profile

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DUO-E
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 18 Mar 2024 According to an AstraZeneca media release, Hye Sook Chon, gynaecologic oncologist at the Moffitt Cancer Center in Tampa, Florida, is a trial investigator.
    • 18 Mar 2024 According to an AstraZeneca media release, results of this trial assessing post-hoc exploratory subgroup will be presented today in a late-breaking session at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Womens Cancer in San Diego, California.
    • 18 Mar 2024 Results published in the AstraZeneca Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top